mProX™ Human AURKA Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1030	Magic™ Human AurA(AURKA) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

AURKA

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MDA-MB-231; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research; Digestive and Renal Research

Related Diseases

Colorectal Cancer and Plasma Cell Neoplasm. Among its related pathways are Regulation of activated PAK-2p34 by proteasome mediated degradation and Cell Cycle, Mitotic

Gene ID

6790

UniProt ID

O14965

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The AURKA gene in humans codes for the enzyme aurora kinase A, sometimes referred to as serine/threonine-protein kinase 6. A family of mitotic serine/threonine kinases includes Aurora A. It is connected to crucial meiosis and mitotic processes, the proper operation of which is essential for normal cell division. One or more phosphorylations can activate Aurora A, and this activation peaks in the cell cycle during the transition from the G2 to the M phases. Early in the S phase and late in the G1 phase, Aurora A localizes close to the centrosome. During telophase, Aurora A stays connected to the spindles. Aurora A relocalizes to the spindle's mid-zone just before mitotic departure. The customized AURKA stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Newman

This AURKA cell line can be applied well according to experimental needs. Nov 17 2022

chat Verified Customer

chat Carl

Using the AURKA cell line from Creative Biolabs has been a game-changer for our research. May 14 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 hnRNP K is required for AURKA to activate MYC transcription and enhance BCSC phenotype.

HA-tagged AURKA overexpressed in MDA-MB-231 cells was transfected using NCsiRNA or hnRNP K. Cells were transfected with pRL-TK for an additional 24 hours along with either the basic reporter (Vec) or the MYC promoter reporter (MYC).

Ref: Zheng, Feimeng, et al. "Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype." Nature communications 7.1 (2016): 10180.

Pubmed: 26782714

DOI: 10.1038/ncomms10180

Research Highlights

Preclinical research has been conducted on several AURKA inhibitors (AKIs), and a number of them have undergone clinical trials either as monotherapies or in conjunction with conventional chemotherapy or other targeted therapies.
Du, Ruijuan, et al. "Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy." Molecular cancer 20 (2021): 1-27.
Pubmed: 33451333 DOI: 10.1186/s12943-020-01305-3

These results uncover a hitherto unidentified carcinogenic characteristic of the spatially dysregulated AURKA in carcinogenesis and offer a possible treatment avenue to overcome kinase inhibitor resistance.
Zheng, Feimeng, et al. "Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype." Nature communications 7.1 (2016): 10180.
Pubmed: 26782714 DOI: 10.1038/ncomms10180